While pan-PIM inhibitor AZD1897 showed limited activity as monotherapy in AML cell lines and primary samples, including FLT3-ITD+ cells, combination of AZD1897 with Akt inhibitor AZD5363 displayed synergistic anti-leukemic activity [293]. The gene discussed is FLT3; the disease is acute myeloid leukemia.